TR200001880T2 - İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi. - Google Patents

İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.

Info

Publication number
TR200001880T2
TR200001880T2 TR2000/01880T TR200001880T TR200001880T2 TR 200001880 T2 TR200001880 T2 TR 200001880T2 TR 2000/01880 T TR2000/01880 T TR 2000/01880T TR 200001880 T TR200001880 T TR 200001880T TR 200001880 T2 TR200001880 T2 TR 200001880T2
Authority
TR
Turkey
Prior art keywords
preparation
itraconazole
oral
compound
oral preparation
Prior art date
Application number
TR2000/01880T
Other languages
English (en)
Inventor
Young Jung Jae
Hyun Kim Kye
Heo Lee Sang
Woong Hong Ji
Woo Park Jong
Hyun Lee Kyu
Original Assignee
Choongwae Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980027730A external-priority patent/KR100288890B1/ko
Application filed by Choongwae Pharma Corporation filed Critical Choongwae Pharma Corporation
Publication of TR200001880T2 publication Critical patent/TR200001880T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut bulus, mantar karsiti mükemmel bir azol ilaci olan agizdan bir itrakonazol preparasyonuna yönelik bir metot ve kompozisyonla ilgilidir. Daha özel olarak bu , gelismis biyo saglanabilirlige sahip agizdan bir itrakonazol preperasyonu ile ilgilidir; bu preperasyon, asagidaki asamalar ile hazirlanir: i) itrakonazol ve hidrofilik çözücü ile çözündürülmesi, ii) adi geçen karisimin spreyle kurutulmasi, ve iii) agizdan preparasyon için kati yayilimlar hazirlanmasi. Bu bulus dahilinde hazirlanan kati yayilimlar; tabletler, granüler ve diger agizdan dozaj formlarinin hazirlanmasinda faydali olabilir.
TR2000/01880T 1997-12-31 1998-12-17 İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi. TR200001880T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19970081947 1997-12-31
KR1019980027730A KR100288890B1 (ko) 1997-12-31 1998-07-10 이트라코나졸 경구용 제제 및 그의 제조방법

Publications (1)

Publication Number Publication Date
TR200001880T2 true TR200001880T2 (tr) 2000-11-21

Family

ID=26633347

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01880T TR200001880T2 (tr) 1997-12-31 1998-12-17 İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.

Country Status (14)

Country Link
US (1) US6485743B1 (tr)
EP (1) EP1039909B1 (tr)
JP (1) JP3696087B2 (tr)
CN (1) CN1153570C (tr)
AU (1) AU1511399A (tr)
BR (1) BR9814729A (tr)
CA (1) CA2317106C (tr)
DE (1) DE69808670T2 (tr)
ES (1) ES2185238T3 (tr)
HK (1) HK1034906A1 (tr)
PL (1) PL191181B1 (tr)
PT (1) PT1039909E (tr)
TR (1) TR200001880T2 (tr)
WO (1) WO1999033467A1 (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
AU2331801A (en) * 1999-12-23 2001-07-09 F.H. Faulding & Co. Limited Improved pharmaceutical compositions for poorly soluble drugs
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
ATE319432T1 (de) * 2000-12-22 2006-03-15 Baxter Int Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
NZ536975A (en) 2002-07-04 2006-10-27 Janssen Pharmaceutica Nv Solid dispersions of a poorly soluble bioactive compound comprising two different polymer matrixes
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
ES2283725T5 (es) * 2003-01-14 2014-11-28 Acino Pharma Ag Composición bioequivalente de itraconazol dispersada en un polímero hidrófilo
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
JP5435946B2 (ja) 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ 疾患を処置するためのヘッジホッグ経路アンタゴニスト
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
KR102009698B1 (ko) 2011-12-20 2019-08-13 바이옴 테라퓨틱스 리미티드 진균 감염의 치료를 위한 국소 오일 조성물
KR20200017549A (ko) 2012-06-04 2020-02-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
EP2863911A4 (en) 2012-06-21 2016-07-13 Mayne Pharma Int Pty Ltd ITRACONAZOLE COMPOSITIONS AND METHOD OF DOSING AND METHOD OF USE THEREOF
JP6589086B2 (ja) * 2013-04-12 2019-10-16 ビョーメ セラピューティクス リミテッド 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法
JP6571657B2 (ja) * 2013-08-27 2019-09-04 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
WO2015134822A1 (en) * 2014-03-05 2015-09-11 Professional Compounding Centers Of America Poloxamer-based pharmaceutical compositions for treating wounds
MX2017001671A (es) * 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
CN104688536B (zh) * 2015-02-03 2016-06-08 常州制药厂有限公司 一种伊曲康唑制剂的制备方法
NZ734446A (en) 2015-03-03 2022-12-23 Pharmacyclics Llc Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor
CN106511265A (zh) * 2016-11-16 2017-03-22 北京万全德众医药生物技术有限公司 一种含有伊曲康唑的口服溶液及其制备工艺
WO2019043427A1 (en) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
JPS57171428A (en) 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
JPS63188621A (ja) 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
JPH0774151B2 (ja) 1987-10-12 1995-08-09 三井東圧化学株式会社 薬物の好ましくない官能的性質を隠蔽した散剤の製造方法
GB8908250D0 (en) 1989-04-12 1989-05-24 Fisons Plc Formulations
JP3034592B2 (ja) 1990-11-20 2000-04-17 わかもと製薬株式会社 経口用固形製剤及びその製造法
ATE138561T1 (de) 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
DK0904060T3 (da) * 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed

Also Published As

Publication number Publication date
EP1039909B1 (en) 2002-10-09
BR9814729A (pt) 2002-01-08
PT1039909E (pt) 2003-02-28
DE69808670D1 (de) 2002-11-14
CN1153570C (zh) 2004-06-16
HK1034906A1 (en) 2001-11-09
ES2185238T3 (es) 2003-04-16
CA2317106A1 (en) 1999-07-08
WO1999033467A1 (en) 1999-07-08
JP3696087B2 (ja) 2005-09-14
PL191181B1 (pl) 2006-03-31
US6485743B1 (en) 2002-11-26
EP1039909A1 (en) 2000-10-04
CA2317106C (en) 2004-11-23
CN1285746A (zh) 2001-02-28
PL341566A1 (en) 2001-04-23
DE69808670T2 (de) 2003-07-03
AU1511399A (en) 1999-07-19
JP2001527044A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
TR200001880T2 (tr) İtrakonazolün bir oral preparasyonunun bileşiği ve yöntemi.
TR200200008T2 (tr) Fenofibratı ihtiva eden farmasötik bileşim ve bu bileşimin hazırlanması için yöntem
NO20002133D0 (no) Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler
ATE256681T1 (de) N-heterozyklische derivate als nos inhibitoren
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
GEP20032967B (en) Indolyl-3-Glyoxylic Acid Derivatives As an Antitumor Agent and Pharmaceutical Composition
EP1187599A4 (en) STABLE BENZIMIDAZOLE FORMULATION
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
NO20062019L (no) P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme
CA2281545A1 (en) N-heterocyclic derivatives as nos inhibitors
DK1611892T3 (da) Farmaceutiske sammensætninger indeholdende drospirenon
GEP20094676B (en) Piperidine compounds and pharmaceutical compositions containing them
TR200402067T4 (tr) 1,3-Dihidro-2H-İndol-2-One türevleri ve bunların arjinin-vasopresin alıcılarının V1B veya V1B ve V1A ligandları olarak kullanımları
HUP0300163A2 (hu) Hialuronsav-származékokból kialakított klatrát komplexek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE8004745L (sv) Nya tripeptider, som inverkar pa det centrala nervsystemet, jemte sett for deras framstellning
TR199802626A2 (tr) Yeni farmasötikler.
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
GT199800196A (es) Combinaciones de estatina-eter carboxialquilico.
MY135646A (en) Indolyl derivatives
CN104800183A (zh) 一种阿司匹林肠溶片及其制备方法和应用
AU2002235990A1 (en) Method for producing a floating tablet containing an active principle
Howell et al. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: Structure–activity studies and in vivo efficacy
AU1572301A (en) Cyclopentyl sulfonamide derivatives
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения